BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.
BDSI helps develop technologies designed to deliver increased bioavailability in the treatment of serious and debilitating chronic conditions.
BioErodible MucoAdhesive (BEMA®) technology uses a small polymer film applied to the inner lining of the cheek for rapid drug administration. Delivering medication across the mucous membranes, this bioerodible film helps optimize time-sensitive treatments. It is also beneficial for facilitating the administration of drugs where poor oral absorption is an issue.
New Scientific Information Further Highlights Differentiated Clinical Profile of BELBUCA® (buprenorphine buccal film) RALEIGH, N.C. , Sept. 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients
Read moreRALEIGH, N.C. , Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey , Interim Chief Executive
Read moreSecond Quarter Total Company Net Revenue Increased 23% versus Prior Year to $36.6 Million Second Quarter BELBUCA® Net Sales Increased 34% versus Prior Year to $32.3 Million BELBUCA and Symproic® Each Reach All Time High TRx Volume and Market Share Conference Call and Webcast Scheduled for 8:30 AM
Read moreThere are no events to display
Stay up to date on the latest news
Get started now